The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 24-32 , January 2003

Mast cells: Beyond IgE

Received 7 October 2002 ,Accepted 16 October 2002.

References 

  1. Stevens RL, Austen KF. Recent advances in the cellular and molecular biology of mast cells. Immunol Today. 1989;10:381–386
  2. Castells M, Schwartz LB. Tryptase levels in nasal lavage fluid as an indicator of the immediate allergic response. J Allergy Clin Immunol. 1988;82:348–355
  3. O'Sullivan S, Dahlen B, Dahlen SE, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol. 1996;98:421–422
  4. Casale TB, Wood D, Richerson HB, Zehr B, Zavala D, Hunninghake GW. Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest. 1987;80:1507–1511
  5. Schulman ES, Kagey-Sobotka A, MacGlashan DW, et al.  Heterogeneity of human mast cells. J Immunol. 1983;131:1936–1941
  6. Mencia-Huerta JM, Razin E, Ringlet WE, et al.  Immunologic and ionophore-induced generation of leukotriene B4 from mouse bone marrow-derived mast cells. J Immunol. 1983;130:1885–1890
  7. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. Slow-reacting substance of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A. 1980;77:3710–3714
  8. Okayama Y, Petit-Frere C, Kassel O, et al.  IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells. J Immunol. 1995;155:1796–1808
  9. Toru H, Pawankar R, Ra C, Yata J, Nakahata T. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol. 1998;102:491–502
  10. Kobayashi H, Okayama Y, Ishizuka T, Pawankar R, Ra C, Mori M. Production of IL-13 by human lung mast cells in response to Fcϵ receptor cross-linkage. Clin Exp Allergy. 1998;28:1219–1227
  11. Ibrahim MZ, Reder AT, Lawand R, Takash W, Sallouh-Khatib S. The mast cells of the multiple sclerosis brain. J Neuroimmunol. 1996;70:131–138
  12. Arbustini E, Gavazzi A, Dal Bello B, et al.  Ten-year experience with endomyocardial biopsy in myocarditis presenting with congestive heart failure: frequency, pathologic characteristics, treatment and follow-up. Gior Ital Cardiol. 1997;27:209–223
  13. Gotis-Graham I, McNeil HP. Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum. 1997;40:479–489
  14. Woolley DE, Tetlow LC. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res. 2000;2:65–74
  15. Algermissen B, Hermes B, Feldmann-Boeddeker I, Bauer F, Henz BM. Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars. Exp Dermatol. 1999;8:193–198
  16. Pesci A, Bertorelli G, Gabrielli M, Olivieri D. Mast cells in fibrotic lung disorders. Chest. 1993;103:989–996
  17. Matsunaga Y, Kawasaki H, Terada T. Stromal mast cells and nerve fibers in various chronic liver diseases: relevance to hepatic fibrosis. Am J Gastroenterol. 1999;94:1923–1932
  18. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;97:1689–1692
  19. Hara M, Ono K, Hwang MW, et al.  Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375–381
  20. Secor VH, Secor WE, Gutekunst CA, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med. 2000;191:813–822
  21. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature. 1996;381:75–79
  22. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature. 1996;381:77–80
  23. Blair RJ, Meng H, Marchese MJ, et al.  Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest. 1997;99:2691–2700
  24. Noli C, Miolo A. The mast cell in wound healing. Vet Dermatol. 2001;12:303–313
  25. Ruitenberg EJ, Elgersma A. Absence of intestinal mast cell response in congenitally athymic mice during Trichinella spiralis infection. Nature. 1976;264:258–260
  26. Lantz CS, Boesiger J, Song CH, et al.  Role for interleukin-3 in mast cell and basophil development and in immunity to parasites. Nature. 1998;392:90–93
  27. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346:1699–1705
  28. Rottem M, Okada T, Goff JP, Metcalfe DD. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/FcER1- population. Blood. 1994;84:2489–2496
  29. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol. 1991;146:1410–1415
  30. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13). Blood. 1999;94:2333–2342
  31. Gurish MF, Tao H, Abonia JP, et al.  Intestinal mast cell progenitors require CD49d/β7 (α4β7 integrin) for tissue-specific homing. J Exp Med. 2001;194:1243–1252
  32. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell. 1988;55:185–192
  33. Huang E, Nocka K, Beier DR, et al.  The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell. 1990;63:225–233
  34. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol. 1994;153:3717–3723
  35. Lorentz A, Schuppan D, Gebert A, Manns MP, Bischoff SC. Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood. 2002;99:966–972
  36. Yee NS, Paek I, Besmer P. Role of kit -ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice. J Exp Med. 1994;179:1777–1787
  37. Irani A-MA, Nillson G, Miettinen U, et al.  Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood. 1992;80:3009–3021
  38. Mitsui H, Furitsu T, Dvorak AM, et al.  Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci U S A. 1993;90:735–739
  39. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood. 1978;52:447–452
  40. Kitamura Y, Go S. Decreased production of mast cells in Sl/Sld anemic mice. Blood. 1979;53:492–497
  41. Malaviya R, Gao Z, Thankavel K, van der Merwe PA, Abraham SN. The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Proc Natl Acad Sci U S A. 1999;96:8110–8115
  42. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by toll-like receptor 4. J Immunol. 2001;167:2250–2256
  43. Gommerman JL, Oh DY, Zhou X, et al.  A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol. 2000;165:6915–6921
  44. Supajatura V, Ushio H, Nakao A, et al.  Differential responses of mast cell toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest. 2002;109:1351–1359
  45. Huang C, De Sanctis GT, O'Brien PJ, et al.  Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung. J Biol Chem. 2001;276:26276–26284
  46. Malaviya R, Abraham SN. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol. 2000;67:841–846
  47. Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol. 1996;156:275–283
  48. Hoek KL, Cassell GH, Duffy LB, Atkinson TP. Mycoplasma pneumoniae -induced activation and cytokine production in rodent mast cells. J Allergy Clin Immunol. 2002;109:470–476
  49. Bidri M, Vouldoukis I, Mossalayi MD, Debre P, Guillosson JJ, Mazier D, et al.  Evidence for direct interaction between mast cells and Leishmania parasites. Parasite Immunol. 1997;19:475–483
  50. Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest. 1997;99:1313–1321
  51. Brown JK, Jones CA, Rooney LA, Caughey GH, Hall IP. Tryptase's potent mitogenic effects in human airway smooth muscle cells are via nonproteolytic actions. Am J Physiol Lung Cell Mol Physiol. 2002;282:L197–L206
  52. Garbuzenko E, Nagler A, Pickholtz D, et al.  Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy. 2002;32:237–246
  53. Finkelman FD, Shea-Donohue T, Goldhill J, et al.  Cytokine regulation of host defense against parasitic gastrointestinal nematodes. Ann Rev Immunol. 1997;15:505–533
  54. Irani AM, Craig S, DeBlois G, Elson CO, Schechter NM, Schwartz LB. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J Immunol. 1987;138:4381–4386
  55. Madden KB, Urban JF, Ziltener HJ, Schrader JW, Finkelman FD, Katona IM. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immunol. 1991;147:1387–1391
  56. Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med. 1998;188:1307–1320
  57. Friend DS, Ghildyal N, Austen KF, Gurish MF, Matsumoto R, Stevens RL. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J Cell Biol. 1996;135:279–290
  58. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis. 1993;147:697–704
  59. Anderson DF, MacLeod JD, Baddeley SM, et al.  Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration. Clin Exp Allergy. 1997;27:1060–1066
  60. Amin K, Rinne J, Haahtela T, et al.  Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration. J Allergy Clin Immunol. 2001;107:249–257
  61. Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a Th2-type allergic inflammatory response. J Allergy Clin Immunol. 2002;108:954–961
  62. Yanagida M, Fukamachi H, Ohgami K, et al.  Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood. 1995;86:3705–3714
  63. Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA. T helper type-2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med. 1999;190:267–280
  64. Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A. 1999;96:8080–8085
  65. Gebhardt T, Sellge G, Lorentz A, Manns MP, Bischoff SC. Cultured human intestinal mast cells express functional IL-3 receptors and respond to IL-3 by enhancing growth and IgE-dependent mediator release. Eur J Immunol. 2002;32:2308–2316
  66. Kirshenbaum AS, Worobec AS, Davis TA, Goff JP, Semere T, Metcalfe DD. Inhibition of human mast cell growth and differentiation by interferon gamma-1b. Exp Hematol. 1998;26:245–251
  67. Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: up-regulation by IFN-gamma. J Immunol. 2000;164:4332–4339
  68. Noguchi E, Shibasaki M, Kamioka M, et al.  New polymorphisms of haematopoietic prostaglandin D synthase and human prostanoid DP receptor genes. Clin Exp Allergy. 2002;32:93–96
  69. Hirai H, Tanaka K, Yoshie O, et al.  Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193:255–261
  70. Lynch KR, O'Neill GP, Liu Q, et al.  Characterization of the human cysteinyl leukotriene cysLT1 receptor. Nature. 1999;399:789–793
  71. Heise CE, O'Dowd BF, Figueroa DJ, et al.  Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531–30536
  72. Davidson AB, Lee TH, Scanlon PD, et al.  Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis. 1987;135:333–337
  73. Griffin M, Weiss JW, Leitch AG, et al.  Effect of leukotriene D4 on the airways in asthma. N Engl J Med. 1983;308:436–439
  74. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341:989–990
  75. Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol. 1983;80:115–119
  76. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucous from human airways in vitro. Am Rev Respir Dis. 1982;126:4449–4451
  77. Henderson WR, Tang LO, Chu SJ, et al.  A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002;165:108–116
  78. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group JAMA. 1996;275:931–936
  79. Altman LC, Munk Z, Seltzer J, et al.  A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol. 1998;102:50–56
  80. Hamilton A, Faiferman I, Stober P, Watson RM, O'Byrne PM. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol. 1998;102:177–183
  81. Lawrence ID, Warner JA, Cohan VL, Hubbard WC, Kagey-Sobotka A, Lichtenstein LM. Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J Immunol. 1987;139:3062–3069
  82. MacGlashan DW, Schleimer RP, Peters SP, et al.  Generation of leukotrienes by purified lung mast cells. J Clin Invest. 1982;70:747–751
  83. Peters SP, MacGlashan DW, Schulman ES, et al.  Arachidonic acid metabolism in purified human lung mast cells. J Immunol. 1984;132:1972–1979
  84. Fox CC, Dvorak AM, Peters SP, Kagey-Sobotka A, Lichtenstein LM. Isolation and characterization of human intestinal mucosal mast cells. J Immunol. 1985;135:483–491
  85. Massey WA, Guo C-B, Dvorak AM, et al.  Human uterine mast cells. Isolation, purification, characterization, ultrastructure, and pharmacology. J Immunol. 1991;147:1621–1627
  86. Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 1990;142:112–119
  87. Clark JD, Lin L-L, Kriz RW, et al.  A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell. 1991;65:1043–1051
  88. Malavia R, Malavia R, Jakschik BA. Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. J Biol Chem. 1993;268:4939–4944
  89. Dixon RAF, Diehl RE, Opas E, et al.  Requirement of a 5-lipoxygenase-activating protein for leukotriene biosynthesis. Nature. 1990;343:282–284
  90. Evans JF, Dupuis P, Ford-Hutchinson AW. Purification and characterization of leukotriene A4 hydrolase from rat neutrophils. Biochem Biophys Acta. 1985;840:43–50
  91. Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A. 1994;91:7663–7667
  92. Lam BK, Xu K, Atkins MB, Austen KF. Leukotriene C4 uses a probenecid-sensitive export carrier that does not recognize leukotriene B4. Proc Natl Acad Sci U S A. 1992;89:11598–11602
  93. Raulf M, Stuning M, Konig W. Metabolism of leukotrienes by L-gamma-glutamyl-transpeptidase and dipeptidase from human polymorphonuclear granulocytes. Immunology. 1985;55:135–147
  94. Penrose JF, Spector J, Baldasaro M, et al.  Molecular cloning of the gene for human leukotriene C4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q35. J Biol Chem. 1996;271:11356–11361
  95. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol. 2000;23:290–296
  96. Kawagishi Y, Mita H, Taniguchi M, et al.  Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol. 2002;109:936–942
  97. Van Sambeek R, Stevenson DD, Baldasaro M, et al.  5′ flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol. 2000;106:72–76
  98. Sampson AP, Siddiqui S, Buchanan D, et al.  Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 2000;55(suppl 2):S28–S31
  99. Toru H, Ra C, Nonoyama S, Suzuki K, Yata J, Nakahata T. Induction of the high-affinity IgE receptor (FcϵRI) on human mast cells by IL-4. Int Immunol. 1996;8:1367–1373
  100. Hsieh FH, Lam BK, Penrose JF, Austen KF, Boyce JA. T helper cell type 2 cytokines coordinately regulate IgE- dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C4 synthase expression by interleukin 4. J Exp Med. 2001;193:123–133
  101. Ochi H, De Jesus NH, Hsieh F, Austen KF, Boyce JA. Interleukins 4 and 5 prime human mast cells for different profiles of IgE-dependent cytokine production. Proc Natl Acad Sci U S A. 2000;97:10509–10513
  102. Lee TH, Austen KF, Corey EJ, Drazen JM. Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to his-tamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci U S A. 1984;81:4922–4925
  103. Dahlen SE, Back M. Leukotriene receptors: functional aspects and future targets. Clin Exp Allergy Rev. 2001;2:137–141
  104. Von Kugelgen I, Wetter A. Molecular pharmacology of P2Y-receptors. Naunyn-Schmiedeberg's Arch Pharmacol. 2000;362:310–323
  105. Foster CJ, Prosser DM, Agans JM, et al.  Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1591–1598
  106. Tominaga M, Wada M, Masu M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci U S A. 2001;98:6951–6956
  107. Warny M, Aboudola S, Robson SC, et al.  P2Y6 nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. J Biol Chem. 2001;276:26051–26056
  108. Mellor EA, Maekawa A, Austen KF, Boyce JA. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci U S A. 2001;98:7964–7969
  109. Maier R, Glatz A, Mosbacher J, Bilbe G. Cloning of P2Y6 cDNAs and identification of a pseudogene: comparison of P2Y receptor subtype expression in bone and brain tissues. Biochem Biophys Res Commun. 1997;240:298–302
  110. Figueroa DJ, Breyer RM, Defoe SK, et al.  Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med. 2001;163:226–233
  111. Mellor EA, Austen KF, Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med. 2002;195:583–592
  112. Bischoff SC, Sellge G, Manns MP, Lorentz A. Interleukin 4 induces a switch of human intestinal mast cells from proinflammatory cells to Th2-type cells. Int Arch Allergy Immunol. 2001;124:151–154

☆ Supported by National Institutes of Health grants AI31599, HL36110, AI48802, and AI52353 and by grants from the Charles Dana Foundation and the Vinik Family Fund for Research in Allergic Diseases in Children.

☆☆ Reprint requests: Joshua A. Boyce, MD, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Smith Research Building, Room 626, 1 Jimmy Fund Way, Boston, MA 02199.

PII: S0091-6749(02)91322-9

doi: 10.1067/mai.2003.60

The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 24-32 , January 2003

Article Tools

* Image Usage & Resolution